Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156008 | 0.82 | KDM4E (0.52) | TAAR1KDM4ERAB9AGRIN2DGRIN3B | |
| SCHEMBL2475493 | 0.82 | GRIN2D (0.53) | TAAR1KDM4ERAB9AGRIN2DGRIN3B | |
| SCHEMBL3155805 | 0.80 | TAAR1 (0.42) | TAAR1KDM4ERAB9A | |
| SCHEMBL1847009 | 0.80 | TAAR1 (0.49) | TAAR1HTR1A | |
| SCHEMBL3176867 | 0.75 | DYRK1A (0.39) | TAAR1KDM4ERAB9AGRIN1GRIN2B | |
| SCHEMBL2473033 | 0.75 | TAAR1 (0.40) | TAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL8913586 | 0.74 | GRIN2D (0.69) | RAB9APNMTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL11288609 | 0.73 | TAAR1 (0.50) | TAAR1PNMT | |
| SCHEMBL3175805 | 0.73 | DPP4 (0.40) | TAAR1KDM4ERAB9AGRIN2DGRIN3B | |
| SCHEMBL1157274 | 0.73 | PNMT (0.45) | PNMTGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076496-B1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | claimed |
| EP-2076496-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | claimed |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | claimed |
| WO-2008046756-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | claimed |
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463359-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | Purdue Pharma LP (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017210616-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | PURDUE PHARMA L.P. (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-2076496-B1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-2076496-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
| WO-2008046756-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201410-A1 | TRACE AMINE ASSOCIATED RECEPTOR 1 AGONISTS AND PARTIAL AGONISTS FOR PAIN TREATMENT | TAAR1, TAAR5, OPRL1 | TAAR1 1/4885KDM4E 3900/4885RAB9A 2991/4885 |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HTR2C, AHR, HAX1 | TAAR1 60/4885KDM4E 905/4885RAB9A 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.